\-\ Texto\\:\\ \ \(0\)\
\-\ calcium\\,\\ ionized\\ \\-\\ low\ \(0\)\
\-\ serum\\ phosphorus\\ \\-\\ low\ \(0\)\
\-\ serum\\ alkaline\\ phosphatase\\ \\-\\ elevated\ \(0\)\
\-\ treatment\\:\\ administered\\ gradually\\ over\\ several\\ months\\ or\\ in\\ a\\ single\\ day\\'s\\ dose\\ with\\ 15\\,000\\ mcg\\ \\(600\\,000\\ u\\)\\ of\\ vitamin\\ d\\.\\ if\\ the\\ gradual\\ method\\ is\\ chosen\\,\\ 125\\-250\\ mcg\\ \\(5000\\-10\\,000\\ u\\)\\ is\\ given\\ daily\\ for\\ 2\\-3\\ months\\ until\\ healing\\ is\\ well\\ established\\ and\\ the\\ alkaline\\ phosphatase\\ concentration\\ is\\ approaching\\ the\\ reference\\ range\\.\\ because\\ this\\ method\\ requires\\ daily\\ treatment\\,\\ success\\ depends\\ on\\ compliance\\.\ \(0\)\
\-\ an\\ alternative\\ and\\ recommended\\ therapy\\ is\\ to\\ administer\\ the\\ vitamin\\ d\\ in\\ a\\ single\\ day\\,\\ usually\\ divided\\ into\\ 4\\ or\\ 6\\ oral\\ doses\\.\\ an\\ intramuscular\\ injection\\ also\\ is\\ available\\.\\ vitamin\\ d\\ is\\ well\\ stored\\ in\\ the\\ body\\ and\\ released\\ gradually\\ over\\ many\\ weeks\\.\\ neither\\ calcitriol\\ nor\\ calcidiol\\ with\\ their\\ short\\ half\\-lives\\ are\\ suitable\\.\\ \ \(0\)\
\-\ prevention\\:\\ 10\\ mcg\\ \\(400u\\)\\ po\\ daily\\ vitamin\\ d\\ preparation\\ and\\ an\\ adequate\\ dietary\\ supply\\ of\\ calcium\\ and\\ phosphorus\\ prevent\\ rickets\\.\\ as\\ little\\ as\\ 20\\ min\\/d\\ of\\ ultraviolet\\ light\\ to\\ the\\ face\\ of\\ a\\ light\\-skinned\\ baby\\ is\\ sufficient\\;\\ however\\,\\ significantly\\ longer\\ periods\\ of\\ exposure\\ are\\ necessary\\ for\\ children\\ with\\ melanotic\\ skin\\.\ \(0\)\
\-\ bilateral\\ wrists\\,\\ knees\\:\\ there\\ is\\ loss\\ of\\ the\\ zone\\ of\\ provisional\\ calcification\\ in\\ the\\ metaphyses\\ with\\ slight\\ irregularity\\ and\\ cupping\\ of\\ the\\ metaphyses\\ of\ \(0\)\
\-\ all\\ the\\ bones\\ imaged\\.\\ there\\ is\\ also\\ apparent\\ widening\\ of\\ the\\ physes\\.\\ thin\\ periosteal\\ reaction\\ along\\ the\\ radial\\ aspect\\ of\\ the\\ distal\\ ulna\\,\\ likely\\ healing\\ insufficiency\\ fracture\\.\ \(0\)\
\-\ rickets\ \(46\)\
\-\ failure\\ of\\ osteoid\\ calcification\\ \\(rickets\\)\\ \\(secondary\\ to\\ a\\ disorder\\ in\\ the\\ pathway\\ of\\ either\\ vitamin\\ d\\ or\\ phosphate\\ metabolism\\)\\:\ \(0\)\
\-\ 1\\.\\ familial\\ hypophosphatemia\\ \\(formerly\\ vitamin\\ d\\â\\€\\“resistant\\ rickets\\)\\ \ \(0\)\
\-\ 2\\.\\ vitamin\\ d\\â\\€\\“dependent\\ rickets\\ type\\ i\\ \ \(0\)\
\-\ 3\\.\\ receptor\\ defect\\ rickets\\ \\(formerly\\ vitamin\\ d\\â\\€\\“dependent\\ rickets\\ type\\ ii\\)\\ \ \(0\)\
\-\ 4\\.\\ defective\\ 25\\-hydroxylase\\ \ \(0\)\
\-\ 5\\.\\ fanconi\\ syndrome\\ \\(rta\\ with\\ phosphate\\ wasting\\)\ \(0\)\
\-\ 6\\.\\ osteodystrophy\\ \\(ie\\,\\ renal\\ rickets\\)\\ and\\ hypophosphatasia\ \(0\)\
\-\ male\\ infant\\ with\\ hypocalcemia\\.\\ breast\\-fed\\ without\\ oral\\ supplementation\\.\ \(0\)\
\-\ human\\ milk\\ contains\\ little\\ vitamin\\ d\\,\\ and\\,\\ for\\ babies\\ weighing\\ less\\ than\\ 1500\\ g\\,\\ it\\ also\\ contains\\ too\\ little\\ phosphate\\.\\ special\\ supplementation\\ \\(vitamin\\ d\\,\\ calcium\\,\\ phosphate\\)\\ is\\ important\\ if\\ breast\\ milk\\ is\\ primary\\ dietary\\ source\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ vitamin\\:\\ 0\\.4472923649883005\ \(0\)\
\-\ rickets\\:\\ 0\\.3759006836134865\ \(0\)\
\-\ phosphate\\:\\ 0\\.21907326735731433\ \(0\)\
\-\ mcg\\:\\ 0\\.17984051715533317\ \(0\)\
\-\ is\\:\\ 0\\.14005298427055482\ \(0\)\
\-\ little\\:\\ 0\\.12575924149388132\ \(0\)\
\-\ daily\\:\\ 0\\.121231201522185\ \(0\)\
\-\ the\\:\\ 0\\.11905219578848134\ \(0\)\
\-\ formerly\\:\\ 0\\.11759034991601316\ \(0\)\
\-\ calcium\\:\\ 0\\.11547731778769159\ \(0\)\
\-\ phosphorus\\:\\ 0\\.10953663367865717\ \(0\)\
\-\ supplementation\\:\\ 0\\.10953663367865717\ \(0\)\
\-\ of\\:\\ 0\\.10842063757642238\ \(0\)\
\-\ milk\\:\\ 0\\.1052380718606275\ \(0\)\
\-\ metaphyses\\:\\ 0\\.1043322153282699\ \(0\)\
\-\ dietary\\:\\ 0\\.09981551742255838\ \(0\)\
\-\ phosphatase\\:\\ 0\\.09798358658287697\ \(0\)\
\-\ alkaline\\:\\ 0\\.09584536567338761\ \(0\)\
\-\ method\\:\\ 0\\.09397517090337162\ \(0\)\
\-\ gradually\\:\\ 0\\.0888225448288606\ \(0\)\
\-\ contains\\:\\ 0\\.08297304544162039\ \(0\)\
\-\ healing\\:\\ 0\\.07959679073190266\ \(0\)\
\-\ serum\\:\\ 0\\.07643140574603023\ \(0\)\
\-\ light\\:\\ 0\\.07382077507419584\ \(0\)\
\-\ and\\:\\ 0\\.07045101715062387\ \(0\)\
\-\ oral\\:\\ 0\\.0682649187346716\ \(0\)\
\-\ 400u\\:\\ 0\\.06815460256766116\ \(0\)\
\-\ ultraviolet\\:\\ 0\\.06815460256766116\ \(0\)\
\-\ rta\\:\\ 0\\.06815460256766116\ \(0\)\
\-\ single\\:\\ 0\\.06554065970817426\ \(0\)\
\-\ administer\\:\\ 0\\.06512536126422687\ \(0\)\
\-\ stored\\:\\ 0\\.06512536126422687\ \(0\)\
\-\ calcitriol\\:\\ 0\\.06512536126422687\ \(0\)\
\-\ melanotic\\:\\ 0\\.06297608035521203\ \(0\)\
\-\ defective\\:\\ 0\\.06297608035521203\ \(0\)\
\-\ breast\\:\\ 0\\.06189513202146497\ \(0\)\
\-\ calcidiol\\:\\ 0\\.06130896856502639\ \(0\)\
\-\ hypocalcemia\\:\\ 0\\.06130896856502639\ \(0\)\
\-\ calcification\\:\\ 0\\.06085397070131352\ \(0\)\
\-\ also\\:\\ 0\\.06013810084424834\ \(0\)\
\-\ hypophosphatemia\\:\\ 0\\.05994683905177773\ \(0\)\
\-\ fanconi\\:\\ 0\\.05994683905177773\ \(0\)\
\-\ babies\\:\\ 0\\.05994683905177773\ \(0\)\
\-\ ionized\\:\\ 0\\.05879517495800658\ \(0\)\
\-\ suitable\\:\\ 0\\.05879517495800658\ \(0\)\
\-\ physes\\:\\ 0\\.05879517495800658\ \(0\)\
\-\ wasting\\:\\ 0\\.05879517495800658\ \(0\)\
\-\ type\\:\\ 0\\.05717884891376336\ \(0\)\
\-\ approaching\\:\\ 0\\.05691759774834342\ \(0\)\
\-\ provisional\\:\\ 0\\.05613044635257725\ \(0\)\
\-\ hypophosphatasia\\:\\ 0\\.055418381300548186\ \(0\)\
\-\ 1500\\:\\ 0\\.055418381300548186\ \(0\)\
\-\ compliance\\:\\ 0\\.05476831683932858\ \(0\)\
\-\ preparation\\:\\ 0\\.05476831683932858\ \(0\)\
\-\ day\\:\\ 0\\.054293186792175534\ \(0\)\
\-\ pathway\\:\\ 0\\.05417031550388763\ \(0\)\
\-\ receptor\\:\\ 0\\.05417031550388763\ \(0\)\
\-\ chosen\\:\\ 0\\.05361665274555744\ \(0\)\
\-\ in\\:\\ 0\\.05300920948671408\ \(0\)\
\-\ doses\\:\\ 0\\.05261903593031375\ \(0\)\
\-\ intramuscular\\:\\ 0\\.05261903593031375\ \(0\)\
\-\ cupping\\:\\ 0\\.05261903593031375\ \(0\)\
\-\ prevention\\:\\ 0\\.05216610766413495\ \(0\)\
\-\ periods\\:\\ 0\\.05216610766413495\ \(0\)\
\-\ human\\:\\ 0\\.05216610766413495\ \(0\)\
\-\ weighing\\:\\ 0\\.051335137794868854\ \(0\)\
\-\ concentration\\:\\ 0\\.050951924140128106\ \(0\)\
\-\ alternative\\:\\ 0\\.050587411442123136\ \(0\)\
\-\ with\\:\\ 0\\.050070193329941115\ \(0\)\
\-\ 10\\:\\ 0\\.04984105675055203\ \(0\)\
\-\ months\\:\\ 0\\.04961362379608338\ \(0\)\
\-\ depends\\:\\ 0\\.049589794626879444\ \(0\)\
\-\ neither\\:\\ 0\\.049589794626879444\ \(0\)\
\-\ if\\:\\ 0\\.04952361113453366\ \(0\)\
\-\ osteodystrophy\\:\\ 0\\.04928481234994247\ \(0\)\
\-\ low\\:\\ 0\\.048908263025699616\ \(0\)\
\-\ an\\:\\ 0\\.04889032537864466\ \(0\)\
\-\ wrists\\:\\ 0\\.04870983423245998\ \(0\)\
\-\ metabolism\\:\\ 0\\.04870983423245998\ \(0\)\
\-\ ie\\:\\ 0\\.04870983423245998\ \(0\)\
\-\ special\\:\\ 0\\.04870983423245998\ \(0\)\
\-\ gradual\\:\\ 0\\.0481759622891864\ \(0\)\
\-\ released\\:\\ 0\\.0481759622891864\ \(0\)\
\-\ divided\\:\\ 0\\.047440513717864605\ \(0\)\
\-\ over\\:\\ 0\\.04739436712926748\ \(0\)\
\-\ sufficient\\:\\ 0\\.04698758545168581\ \(0\)\
\-\ osteoid\\:\\ 0\\.04698758545168581\ \(0\)\
\-\ familial\\:\\ 0\\.04635585481148286\ \(0\)\
\-\ success\\:\\ 0\\.046156615582419715\ \(0\)\
\-\ established\\:\\ 0\\.04596255198800418\ \(0\)\
\-\ imaged\\:\\ 0\\.04577340192767897\ \(0\)\
\-\ ulna\\:\\ 0\\.04577340192767897\ \(0\)\
\-\ or\\:\\ 0\\.04447757044661161\ \(0\)\
\-\ knees\\:\\ 0\\.0444112724144303\ \(0\)\
\-\ administered\\:\\ 0\\.04410629013749333\ \(0\)\
\-\ po\\:\\ 0\\.043670961475013\ \(0\)\
\-\ longer\\:\\ 0\\.04339422508546426\ \(0\)\
\-\ supply\\:\\ 0\\.04286972708108047\ \(0\)\
\-\ too\\:\\ 0\\.04286972708108047\ \(0\)\
\-\ reference\\:\\ 0\\.04169999519539574\ \(0\)\
\-\ nor\\:\\ 0\\.041486522720810194\ \(0\)\
\-\ adequate\\:\\ 0\\.041486522720810194\ \(0\)\
\-\ requires\\:\\ 0\\.04127898081078693\ \(0\)\
\-\ irregularity\\:\\ 0\\.04127898081078693\ \(0\)\
\-\ well\\:\\ 0\\.0412711721794573\ \(0\)\
\-\ zone\\:\\ 0\\.041177332599033716\ \(0\)\
\-\ insufficiency\\:\\ 0\\.04107704883405902\ \(0\)\
\-\ treatment\\:\\ 0\\.04060191878690597\ \(0\)\
\-\ source\\:\\ 0\\.04059487971522983\ \(0\)\
\-\ exposure\\:\\ 0\\.04050207071657653\ \(0\)\
\-\ significantly\\:\\ 0\\.040054570004806465\ \(0\)\
\-\ dose\\:\\ 0\\.03979839536595133\ \(0\)\
\-\ widening\\:\\ 0\\.03931098157978493\ \(0\)\
\-\ prevent\\:\\ 0\\.03907870292345371\ \(0\)\
\-\ for\\:\\ 0\\.03875107866548773\ \(0\)\
\-\ face\\:\\ 0\\.0384222882465394\ \(0\)\
\-\ baby\\:\\ 0\\.0384222882465394\ \(0\)\
\-\ infant\\:\\ 0\\.037628157842031225\ \(0\)\
\-\ periosteal\\:\\ 0\\.03750363782098605\ \(0\)\
\-\ slight\\:\\ 0\\.03732066471704002\ \(0\)\
\-\ injection\\:\\ 0\\.037083469292966326\ \(0\)\
\-\ short\\:\\ 0\\.036630541026787526\ \(0\)\
\-\ radial\\:\\ 0\\.03657580797382258\ \(0\)\
\-\ reaction\\:\\ 0\\.03625557202432549\ \(0\)\
\-\ important\\:\\ 0\\.03610045859833779\ \(0\)\
\-\ disorder\\:\\ 0\\.0360494616200194\ \(0\)\
\-\ necessary\\:\\ 0\\.035653552926854376\ \(0\)\
\-\ apparent\\:\\ 0\\.035653552926854376\ \(0\)\
\-\ until\\:\\ 0\\.035463197959129555\ \(0\)\
\-\ their\\:\\ 0\\.03536980888917545\ \(0\)\
\-\ either\\:\\ 0\\.03523187829494586\ \(0\)\
\-\ children\\:\\ 0\\.03491961076310197\ \(0\)\
\-\ bones\\:\\ 0\\.034291423413605714\ \(0\)\
\-\ as\\:\\ 0\\.03424189548837056\ \(0\)\
\-\ there\\:\\ 0\\.03391471321899714\ \(0\)\
\-\ recommended\\:\\ 0\\.03390018071100457\ \(0\)\
\-\ many\\:\\ 0\\.033601299723353226\ \(0\)\
\-\ ii\\:\\ 0\\.033601299723353226\ \(0\)\
\-\ thin\\:\\ 0\\.03317426759511255\ \(0\)\
\-\ range\\:\\ 0\\.03307121729490349\ \(0\)\
\-\ failure\\:\\ 0\\.032356051587791514\ \(0\)\
\-\ are\\:\\ 0\\.032342778611419355\ \(0\)\
\-\ to\\:\\ 0\\.03196284675757188\ \(0\)\
\-\ skin\\:\\ 0\\.03170340422998093\ \(0\)\
\-\ defect\\:\\ 0\\.031262182110171406\ \(0\)\
\-\ because\\:\\ 0\\.029784907024152745\ \(0\)\
\-\ given\\:\\ 0\\.029316484051455458\ \(0\)\
\-\ elevated\\:\\ 0\\.029052892618975097\ \(0\)\
\-\ less\\:\\ 0\\.028993362197907106\ \(0\)\
\-\ available\\:\\ 0\\.02891471906842558\ \(0\)\
\-\ along\\:\\ 0\\.028552069237483012\ \(0\)\
\-\ body\\:\\ 0\\.02804780850844205\ \(0\)\
\-\ several\\:\\ 0\\.027961237107385427\ \(0\)\
\-\ 20\\:\\ 0\\.027494145750111866\ \(0\)\
\-\ aspect\\:\\ 0\\.027494145750111866\ \(0\)\
\-\ usually\\:\\ 0\\.02682927250641229\ \(0\)\
\-\ renal\\:\\ 0\\.02653909901195529\ \(0\)\
\-\ primary\\:\\ 0\\.026205142709572533\ \(0\)\
\-\ loss\\:\\ 0\\.025964120894472798\ \(0\)\
\-\ syndrome\\:\\ 0\\.025692417195121123\ \(0\)\
\-\ weeks\\:\\ 0\\.025541482196711596\ \(0\)\
\-\ likely\\:\\ 0\\.025467142993163626\ \(0\)\
\-\ all\\:\\ 0\\.025369160889550144\ \(0\)\
\-\ secondary\\:\\ 0\\.025260445543847602\ \(0\)\
\-\ however\\:\\ 0\\.02522455582719859\ \(0\)\
\-\ distal\\:\\ 0\\.02476180556726683\ \(0\)\
\-\ therapy\\:\\ 0\\.02448649702909248\ \(0\)\
\-\ fracture\\:\\ 0\\.02422097411877174\ \(0\)\
\-\ than\\:\\ 0\\.02415862859717826\ \(0\)\
\-\ bilateral\\:\\ 0\\.022904197706786554\ \(0\)\
\-\ into\\:\\ 0\\.022654710136316345\ \(0\)\
\-\ without\\:\\ 0\\.0224791098930175\ \(0\)\
\-\ it\\:\\ 0\\.02181528409374789\ \(0\)\
\-\ male\\:\\ 0\\.018974934333075667\ \(0\)\
\-\ this\\:\\ 0\\.014644128061389955\ \(0\)\
\-\ on\\:\\ 0\\.012871205604021317\ \(0\)\
